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Abstract Gene-encoded peptide antibiotics have been isolated
from plants, animals and microbes. Their protective role has been
related to innate immunity, which has gradually become accepted
across the biomedical community. The evidence for the immune
function of peptide antibiotics has been convincingly demon-
strated by a combination of both in vitro and in vivo data for
plants and insects, but for vertebrates in vivo data are scarce.
Using frogs as model systems, it has been shown that the genes
for antibacterial peptides are down-regulated by glucocorticoids,
while IUBK is clearly up-regulated. Experimental infections with
frog bacteria have shown that the normal capacity to control the
natural flora is lost after treatment with glucocorticoids. A low-
specificity immune mechanism is cost-effective, something that
may have been of importance during animal evolution.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Gene-encoded peptide antibiotics have ¢nally come of age.
The number of such peptides identi¢ed has rapidly grown to
several hundreds in the last years, being isolated from plants,
animals and microbes (for reviews, see [1^4]). They are known
to protect the host against infections and this role was ¢rst
demonstrated in insects [5]. In plants this protection has been
exploited through genetic engineering to prevent fungal or
bacterial infections of crops [2]. When it comes to vertebrates
and mammals, quite a number of peptides have been isolated
and proven to be highly e¡ective in vitro, but currently in vivo
data are scarce.
The protective role of peptide antibiotics has been related to
immunity and the concept of ‘innate immunity’ has gradually
become accepted throughout the biomedical community. The
evidence for the immune function of peptide antibiotics has
been convincingly demonstrated by both in vitro and in vivo
experiments in insects [6,7]. In the case of the ¢rst animal
peptides isolated in the beginning of the 1980s [8,9], their
role in immunity was clearly identi¢ed. In humans, this dem-
onstration was recently provided by the ¢nding that terminal
infections of airways with Pseudomonas aeruginosa in patients
with cystic ¢brosis is due to salt inactivation of the human L-
defensin 1 [10].
2. The superfamilies of peptide antibiotics
Chemically speaking peptide antibiotics can be divided in
three main classes, one may say superfamilies, because the
sequence similarities within each group are almost negligible.
Rather it is the gross composition and the 3D structure that
form the basis for their grouping, as illustrated in Fig. 1.
2.1. Group I: linear, K-helical peptides without cysteines
This family includes the cecropins [1], the magainin/PGLa-
like peptides [11,12], the bombinins [13^15] and the smaller
temporins [16]. The sequences of temporin B and the bomb-
inin-like peptide, BLP-3, as described by Gibson et al. [14],
are given in Fig. 1 and their antibacterial activity in Table 1.
2.2. Group II: peptides with an even number of cysteines
intralinked by disul¢de bridges
The number of such bonds can vary from one to four.
Peptides with one disul¢de forming a C-terminal loop are
chie£y found in frog skin secretions (brevinins, esculentins
[17]). The sequences of brevinin 2E [18] and brevinin 2T
from Rana temporaria (unpublished), as well as their activities,
are reported in Fig. 1 and Table 1, respectively. Examples of
peptides with two disul¢de bridges are the tachyplesins from
horseshoe crab [19] and the protegrins from pig [4]. The best
studied within the Cys-containing group are the mammalian
defensins with three S^S bonds. Interestingly, in K- and L-
defensins two di¡erent disul¢de arrangements (see Fig. 1)
can give almost the same antiparallel L-sheet structure. These
molecules have been very well studied in a number of mam-
mals, including humans [4]. The K-defensins are synthesized
during the maturation of neutrophils and then stored in spe-
cial granules, while the L-defensins are made in the epithelia
of the airways and the intestine. Insects and plants also have
defensins, in these cases comprising a short K-helix packed on
one side of the antiparallel L-sheet structure.
2.3. Group III: peptides with an unusually high proportion of
one or two amino acids, most often Pro and Arg together
The porcine PR-39 is multifunctional, with a potent anti-
biotic activity, a wound healing function and an antioxidant
role [20^22]. There are larger cousins of PR-39 called Bac5
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and Bac7 from cow [23]. The latter animal also makes indo-
licidin, a 13 amino acid peptide containing ¢ve Trp residues
[24].
3. Peptide precursors
All gene-encoded peptide antibiotics are made as inactive
precursors, usually 2^5 times larger than the active e¡ector
molecules. It has often been found that di¡erent peptides
from related animals have proparts with highly conserved
sequences. Cathelicidins from mammals are an example of a
highly variable peptide family with at least 20 members, all
having a strongly conserved propart [25]. Both PR-39, Bac5,
Bac7 and indolicidin belong to the family of cathelicidins.
Four gene sequences (one human and three from pig) show
that the conserved information for the signal and the cathelin
proparts are encoded in the ¢rst three exons, while the vari-
able e¡ector part is in exon 4 [26^28]. In the defensins, the
function of the propart is to direct the mature molecule to the
right type of granules, but the role of the cathelin propart is
not yet fully understood. In both defensins and cathelicidins,
the acidic propart may decrease or prevent the membrane
interaction of the basic e¡ector part [29].
In amphibia it has been shown by cDNA sequencing that
peptides with di¡erent biological activities, either antimicro-
bial or pharmacological, have similar structures in the propart
of their precursor sequences. In di¡erent Rana species, anti-
microbial peptides such as brevinins and esculentins [18], tem-
porins [16] or ranalexin [30], share their propart with peptides
from di¡erent Phyllomedusa species, like dermaseptins [31] or
the opioid peptides dermorphins and deltorphins [32].
4. Gene regulation of peptide antibiotics
Thanks to all the genetic know-how accumulated for Dro-
sophila, this is without comparison the organism in which the
gene control of peptide antibiotics is best understood [6,7].
The promoter regions of inducible peptide antibiotics are
often (or always?) regulated by the transcriptional control
machinery, NFUB-IUBK, originally discovered by Baltimore’s
group and now the subject of intense research activity [33].
This machinery seems to be so strongly conserved that Dro-
sophila, which o¡ers convenient experimental conditions both
with live £ies and cell lines, may serve as a model system for
mammals.
A signi¢cant amount of these regulatory studies has been
done in mammalian cell cultures and this applies also to the
demonstration that glucocorticoids induce a constitutive syn-
thesis of IUBK [34,35]. However, immune function cannot be
reliably studied in cell lines, and consequently genetically
modi¢ed mice are beginning to take central position in works
aimed at understanding the in vivo role of di¡erent cytokines,
perforin and receptors. Mice are known to have 17 di¡erent
enteric defensins [36] and one gene homologous to human L-
defensin 1 has been analyzed [37]. However, mice do not have
peptide antibiotic-containing neutrophils. Despite this fact, it
is universally accepted that mice are the best mammalian dis-
ease models for humans.
In this review, we intend to focus on vertebrates, and par-
ticularly amphibia, that can function as model systems for
gathering both in vivo and in vitro data for the natural func-
tion of peptide antibiotics. In fact, as discussed below, frogs
may o¡er advantages over murine models.
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Fig. 1. Sequences of representative peptide antibiotics from the three main superfamilies. The presence of an amidated C-terminus is indicated
by the asterisk. So far the linear peptides and the Cys-containing peptides represent the two largest groups, numbering more than 100 sequen-
ces each. Only one example of S^S linkage is given for each group of peptides. For four peptides, activities against di¡erent bacteria are given
in Table 1. For available sequences, see a data base: http://www.bbcm.univ.trieste.it/~tossi/ search.html.
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5. Frogs as model systems
Erspamer’s pioneering work showed that frog skins are a
rich source of neuropeptides, many identical to those present
also in human tissues, albeit in much lower quantities [38].
Zaslo¡ realized that frogs have the same capacity to ¢ght
infections [11] as demonstrated 6 years earlier for insects. As
the result of his subsequent work, analogues of magainin from
Xenopus laevis have now passed phase three of clinical trials
and may soon be on the market as human drugs for cutane-
ous infections. However, magainins are unique to X. laevis
and other species of frogs have been found to have a wide
variety of di¡erent antimicrobial peptides in their skin secre-
tion, mostly linear, but some with one pair of intralinked
cysteines [17]. A particular advantage of the frog is that the
skin secretion can be stimulated by a mild electric shock and
the excreted peptides are easily washed o¡, collected and an-
alyzed. Thus, the same animal can be used for repeated ex-
periments, which is not possible with mice. Another advant-
age of frogs is that biosynthesis of active peptides may involve
up to three post-translational modi¢cations: (i) a processing
that gives an N-terminal pyroglutamate, (ii) a C-terminal ami-
dation (taking the amide group from a post-ultimate Gly res-
idue), and (iii) a conversion of an encoded L-amino acid to its
D-isomer [39]. The latter reaction is a fast biochemical way by
which an inactive precursor can be converted in one step to a
potent physiological agent.
We are investigating the natural £ora of frogs. Relatively
few bacterial species are present in a wild animal; four of the
most frequent are listed in the top part of Table 1. They are
all known to be present in the normal £ora of humans. In the
case of Aeromonas hydrophila, it is probably always part of
the normal £ora, but only after viral infections (detected or
undetected) or in individuals with an impaired immune system
can it be diagnosed as a pathogen.
To perform experimental infections, spontaneous and stable
antibiotic-resistant mutants were isolated from A. hydrophila
and Enterobacter agglomerans. These two mutants were used
for double infecting the mouth of Rana esculenta. One set of
frogs was kept as control and another was pretreated with a
glucocorticoid (GC) cream on the skin [40]. The mouth of the
frogs was infected with 2U106 cells of each bacterial strain.
The progression of the infection was monitored by pipetting
20 Wl LB into the frog mouth and quickly withdrawing 5 Wl
‘saliva’ for viable counts. Fig. 2 shows the results of one such
double infection. In the wild healthy frog, in which the bacte-
rial levels are normally 0^5 cfu/5 Wl, there was a small tem-
porary increase (73 and 26 cfu/5 Wl of A. hydrophila and E.
agglomerans, respectively). At day 12, no antibiotic-resistant
bacteria were found in the ‘saliva’ of the control. The GC-
treated frog gave a transient infection with A. hydrophila
(max. 1654 cfu/5 Wl at day 6) and a progressive infection
with E. agglomerans (4400 cfu/5 Wl at day 12). Thus, the nor-
mal capacity to adjust an excess of a natural component of
the £ora is lost after GC treatment.
We know from recent experiments that the genes for frog
antibacterial peptides are down-regulated by GC treatment,
while IUBK is clearly up-regulated [40]. So far, all genes for
inducible peptide antibiotics in animals have been found to
have potential binding sites for NFUB [7,27,37,41,42] and
those of mammals also for NF-IL6. This experiment on am-
phibia implies that frog genes for peptide antibiotics are under
control of the dual NFUB-IUBK system. However, only a few
frog peptide antibiotic genes have been sequenced and in no
case have the promoter regions been discussed.
The peptides and the cDNA of Bombina orientalis [14] and
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Fig. 2. E¡ects of glucocorticoid treatment on the bacterial levels in
the mouth of Rana esculenta frogs, double infected with antibiotic-
resistant strains of Aeromonas hydrophila (triangles) and Entero-
bacter agglomerans (circles). The skin of the GC-treated frog was
given a systemically acting cortisone cream, as reported [40]. Data
for known antibacterial activities against the two infecting bacteria
are given in Table 1.
Table 1
Antibacterial activity of frog skin secretions and some puri¢ed peptides
Organism Strain Skin secretion (cecropin U/mg) Peptide (LC values, WM)






Enterobacter agglomerans Bo-1S 30 50 19 0.9 2.1 1.9 0.6
Aeromonas hydrophila Bo-3N 1.7 1.0 1.5 30.0 30.0 25.7 2.6
Klebsiella pneumoniae Rt-1 30 50 15 2.2 0.5 7.4 0.5
Acinetobacter junii Bo-2 110 140 100 0.2 8.5 1.3 0.6
Escherichia coli D21 270 120 140 0.5 0.5 3.0 0.3
Bacillus megaterium Bm11 s 600 1000 390 0.2 0.2 0.8 5.3
Yersinia pseudotuberculosis Wild type
III
s 600 s 900 s 650 0.1 0.2 0.5 0.5
The ¢rst four organisms are isolates from frog mouth or skin, the next two are our common test bacteria. The Yersinia strain was included as an
example of a human pathogen (kindly provided by Hans Wolf-Watz, Umeaî). The sequences of the four peptides are given in Fig. 1. The
antibacterial activity of the whole secretion is given as cecropin units/mg. The LC value (WM) is the lowest concentration that inhibits growth
in a zone assay. The porcine cecropin P1 was included as a well known reference.
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Bombina variegata [13] were investigated in parallel. We have
recently completed the DNA sequence of two genes in B.
orientalis, encoding two copies each of bombinin-like peptides
and, in addition, two peptides not identi¢ed before [43]. In the
upstream regions, binding sites were found for NFUB, which
was expected, but also for NF-IL6. Experiments to demon-
strate the function of the promoter regions are in progress.
Can Table 1 explain the outcome of the double infection
shown in Fig. 2? So far, the answer is yes, because the skin
secretion of R. esculenta is more than 15 times more e¡ective
in killing E. agglomerans than it is in killing A. hydrophila
(Table 1). The latter is one of the bacteria in the normal £ora
that is most resistant to the peptides tested.
6. When does nature worry about the defense budget of
animalcules?
When comparing innate and acquired immunity it is rele-
vant to ask how much DNA is needed in each case and how
much energy is consumed. If we consider that the same
amounts of ATP and GTP are needed for each peptide
bond formed, we come to a 10-fold di¡erence in energy re-
quirement for making one molecule with 100 amino acid res-
idues compared to one molecule of IgG with around 1000
residues. If we then take into account that the speci¢city of
the peptide antibiotics is relatively wide (perhaps 20^30 di¡er-
ent peptides can protect an animal), while the high speci¢city
of immunoglobulins is quite expensive (estimates run at
around 106 di¡erent antibodies in a mouse), the amount of
chemical energy used by classical immunology is orders of
magnitude larger than that used by innate immunity. Thus,
as long as self-destruction is avoided, a low-speci¢city immune
mechanism is much more cost-e¡ective than one with a max-
imum of speci¢city.
Looking at the DNA, a rough calculation would show that
in order to make an IgG molecule, repertoires of gene seg-
ments are needed which make the completed molecule to re-
quire 13.4 Mb [44]. A family of 20 peptide antibiotics, each
with four assumed processing enzymes, may only need some
130 kb [45] which is in the order of 1%. It is hard to escape
the notion that this has in£uenced the evolution of animals. If
the rate of protein synthesis is more or less a temperature-
dependent constant, then the biomass of a species (number of
individuals and body size) may vary chie£y with evolution
(including microbe interaction). However, body size is critical,
because small animals like insects cannot allow space for rep-
ertoires and large mammals with a slow rate of reproduction
have had to provide the extra DNA needed for classical im-
munity. In this respect, the frogs are a mystery (and perhaps a
border case), because they have lymphocytes and capacity for
a repertoire (shown to produce antibodies for DNP-haptens).
An infection can end in the following three ways, which are
fundamentally di¡erent and may depend on the rate of repro-
duction: (1) the invading microbe is completely eliminated, an
event that is both possible and desirable; (2) a compromise
between the host and the parasitic organism is reached, a
process that is a biological necessity; (3) the infecting organ-
ism is added to the natural £ora, with the physiological reg-
ulation that this would require. For bacteria and alternatives
(1) and (3) there are strong indications that gene-encoded
peptide antibiotics are the e¡ector molecules. Obligate para-
sites like viruses require alternative (2), the compromise, and
that is what most immunologists so far have been preoccupied
with.
Only the future will show to what extent each of these three
alternatives re£ects what goes on in nature in wild animals
and also what was taking place in our ancestors 20 000 years
ago. Moreover, recent estimates indicate that we may know
only about 1% of the microbial world [46]. If the immune
system is supposed to protect us from these microbes and if
most of them are still unknown to us, we could in fact have an
incomplete understanding of what goes on. Also, one or an-
other misinterpretation could stem from some unphysiological
experiments in the past.
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